Physician profile
Ronald M Mann
NPI 1902845738
$4,780.47
in general payments reported to CMS, 2019-2025
21 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $329 · 2021: $481 · 2022: $937 · 2023: $733 · 2024: $1,114 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,560 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,560.27 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,433.48 | 2020-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $675.51 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $504.06 | 2019-2025 | Libtayo |
| Genzyme Corporation | $411.07 | 2020-2023 | |
| Galderma Laboratories, L.P. | $301.54 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $210.69 | 2020-2025 | Blu-U, Odomzo |
| Leo Pharma INC. | $182.60 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $176.16 | 2019-2024 | |
| Amgen INC. | $174.78 | 2022-2025 | Otezla |
| Lilly USA, LLC | $142.22 | 2019-2023 | Taltz |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Janssen Scientific Affairs, LLC | $96.79 | 2022 | |
| Ucb, INC. | $84.60 | 2019-2025 | Bimzelx |
| Biofrontera INC. | $83.10 | 2021-2025 | Ameluz, Bf-Rhodoled, Xepi |
| Dusa Pharmaceuticals, INC. | $55.90 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.76 | 2023 | Keytruda |
| Helsinn Therapeutics (U.S.), INC. | $32.65 | 2023-2024 | Valchlor |
| E.R. Squibb & Sons, L.L.C. | $31.91 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $18.25 | 2024 | Zoryve |
| Misonix INC | $13.42 | 2021 | |
| Organon LLC | $8.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.